Last reviewed · How we verify

morphine solution for injection

Danish University of Pharmaceutical Sciences · FDA-approved active Small molecule

Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and euphoria.

Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and euphoria. Used for Moderate to severe acute and chronic pain, Postoperative pain, Cancer pain.

At a glance

Generic namemorphine solution for injection
SponsorDanish University of Pharmaceutical Sciences
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that modulates pain perception and emotional response to pain by binding to opioid receptors in the brain, spinal cord, and peripheral tissues. This binding inhibits the release of neurotransmitters involved in pain signaling and alters the patient's perception and emotional response to pain. The drug also produces sedation and can suppress cough and respiratory drive.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: